Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis
DOI:
https://doi.org/10.3941/jrcr.v15i2.3918Keywords:
Vigabatrin, Vigabatrin Toxicity, VABAM, Vigabatrin-associated brain abnormalities, Tuberous Sclerosis Complex, Pediatric Neuroimaging, MRIAbstract
Vigabatrin therapy is commonly used in infants diagnosed with tuberous sclerosis complex, particularly in the setting of epilepsy. Utilization of vigabatrin can result in bilateral and symmetric abnormal sequence changes within the deep brain matter and brainstem on magnetic resonance imaging. These abnormalities occur predominantly in infancy, are reversible, and can be asymptomatic or result in symptomatic clinical manifestations. We present a case with classic neuroimaging findings. Familiarity with these findings can prevent unnecessary follow up tests or studies and the cost of continuing or discontinuing vigabatrin therapy should be weighed heavily against the potential manifestation of extrapyramidal symptoms.Downloads
Published
2021-02-20
Issue
Section
Neuroradiology
License
The publisher holds the copyright to the published articles and contents. However, the articles in this journal are open-access articles distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License, which permits reproduction and distribution, provided the original work is properly cited. The publisher and author have the right to use the text, images and other multimedia contents from the submitted work for further usage in affiliated programs. Commercial use and derivative works are not permitted, unless explicitly allowed by the publisher.